These days, the frontier AI labs are all racing to build self-improving models. Some believe it’s the surest route to ...

Learn more about whether Recursion Pharmaceuticals, Inc. or Syndax Pharmaceuticals, Inc. is a better investment based on AAII ...

With Sidewinder, Ares graduated from a scanner that followed a script to an adversary that thinks. Where Dagger marched every target through the same fixed sequence of phases on a single fine-tuned ...

In late June 2026, Recursion Pharmaceuticals, Inc. was added to multiple Russell value and small-cap benchmarks, including ...

Recursion and Exscientia, two pioneers in artificial intelligence (AI)-based drug development, have completed a business combination that they vowed will enhance their ability to carry out drug ...

Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their ...

Spread the love“`html Artificial Intelligence (AI) has transcended its traditional role as a tool for human usage, evolving into a powerful force capable of creating and improving itself. This ...

One way to capitalize on the artificial intelligence (AI) industry is to invest in companies that could benefit from the ...

The companies at the frontier of artificial intelligence should be ready to slow down, one of the fastest-moving among them says. Anthropic, the maker of the Claude chatbot, has claimed AI systems may ...

RSI is also defined as an “AI system capable of fully autonomously designing and developing its own successor,” per Anthropic’s blog post. “We are not there yet, and recursive self-improvement is not ...

Recursive Superintelligence has raised $650 million at a $4.65 billion valuation in a funding round led by GV and Greycroft, according to the company. The round also included participation from AMD ...